• Pacira Biosciences published an investor presentation ahead of its June 9, 2026 annual meeting, with the deck posted at investor.pacira.com.
• The presentation cited 2025 total revenue of $726.4 million, GAAP gross margin of 79.4%, non-GAAP gross margin of 81.2%, EXPAREL volume growth of 8% in the second half, total stockholder return of 22% since the 5x30 plan launch in January 2025.
• It highlighted first-quarter results showing EXPAREL revenue of $143.3 million, up 5% year over year, ZILRETTA revenue of $26.8 million, up 15%, iovera° revenue of $6.2 million, up 21%.
• The deck outlined $200 million returned under a $300 million share repurchase program since April 2025, a volume-limited EXPAREL patent settlement securing exclusivity through 2030, pipeline work on PCRX-201 and PCRX-2002 targeting osteoarthritis and postsurgical pain.
• It said the board added five independent directors since October 2023 and nominated a sixth, which would leave it 89% independent with average tenure of about 4.6 years, while criticizing DOMA Perpetual’s nominees and urging votes for Pacira’s slate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pacira Biosciences Inc. published the original content used to generate this news brief on May 20, 2026, and is solely responsible for the information contained therein.